Autogenous Tumor Infiltrates Lymphocytes(Sino-cell)

N/A

Report date: 2026/04/28 20:00:22

Base Information

Drug NameAutogenous Tumor Infiltrates Lymphocytes(Sino-cell)
Drug Alias NameFAST-TILHSIT-101HS-IT101
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating LymphocytesCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Source of cells > Tumor-derived
Mechanisms of ActionLymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursCarcinoma, Non-Small-Cell Lung +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesQingdao Sino-cell Biomedicine Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesQingdao Sino-cell Biomedicine Co Ltd
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursCarcinoma, Non-Small-Cell Lung +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A